NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2
In two studies of mice, researchers showed that a drug, engineered to combat the gene that causes spinocerebellar ataxia type 2 (SCA2), might also be used to treat amyotrophic lateral sclerosis (ALS). Both studies were published in the journal Nature with funding from National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
“Our results provide hope that we may one day be able to treat these devastating disorders,” said Stefan M. Pulst, M.D., Dr. Med., University of Utah, professor and chair of neurology and a senior author of one the studies. In 1996, Dr. Pulst and other researchers discovered that mutations in the ataxin 2 gene cause spinocerebellar ataxia type 2, a fatal inherited disorder that primarily damages a part of the brain called the cerebellum, causing patients to have problems with balance, coordination, walking and eye movements.
For this study his team found that they could reduce problems associated with SCA2 by injecting mouse brains with a drug programmed to silence the ataxin 2 gene. In the accompanying study, researchers showed that injections of the same type of drug into the brains of mice prevented early death and neurological problems associated with ALS, a paralyzing and often fatal disorder.
“Surprisingly, the ataxin 2 gene may act as a master key to unlocking treatments for ALS and other neurological disorders,” said Aaron Gitler, Ph.D., Stanford University, associate professor and senior author of the second study. In 2010, Dr. Gitler and colleagues discovered a link between ataxin 2 mutations and ALS.
The type of drug they used is called an antisense oligonucleotide. Like an incomplete row of teeth on a zipper, these drugs are short sequences of DNA designed to bind to a portion of a gene’s instructions carried by a molecule called messenger RNA. This stops cells from manufacturing proteins, a process known as gene silencing.
“Our antisense oligonucleotides prevent cells from reading the blueprint for the ataxin 2 gene,” said Daniel R. Scoles, M.D., University of Utah and the lead author of the SCA2 study.
An antisense oligonucleotide drug has been approved by the Food and Drug Administration for treating spinal muscular atrophy, a hereditary disorder that causes arm and leg muscle weakness and deterioration in children. Researchers are conducting early phase clinical trials on the safety and effectiveness of gene silencing drugs to treat several neurological disorders, including Huntington’s disease and an inherited form of ALS.
“Antisense oligonucleotides provide researchers with a promising tool for studying the underlying causes of many disorders and developing gene-targeting treatments,” said Amelie Gubitz, Ph.D., program director at NINDS.
Mutations in ataxin 2 that are associated with SCA2 cause the gene to have polyglutamine expansions, strings of repeated copies of the three letter genetic code, CAG, which stands for the amino acid glutamine. On average, symptoms appear earlier and are more severe for patients who have longer strings. People who have only 27-33 repeats will not develop SCA2 but have an increased risk for ALS.
Dr. Pulst’s team worked with a pharmaceutical company to develop antisense oligonucleotides that silence the ataxin 2 gene rather than the CAG repeats. They then tested oligonucleotides on two lines of mice genetically engineered to have problems associated with SCA2 by programming neurons in the cerebellum to make mutant ataxin 2.
In both lines, the oligonucleotides appeared to be effective. Mice injected with the drug were able to walk on a rotating rod longer than mice that received a placebo. Electrical recordings showed the drug restored the firing patterns of neurons in the cerebellum to normal. In addition to reducing ataxin 2 gene levels, the researchers found that the drug also restored the levels of several genes that appear to be decreased by mutant ataxin 2.
Meanwhile, Dr. Gitler’s team used different mice to test the idea of combating ALS by silencing ataxin 2. These mice were genetically modified to manufacture high levels of the human version of TDP-43, a protein that normally regulates genes. The researchers investigated these mice because neurons from ALS patients often contain toxic clusters of TDP-43. The mice rapidly develop problems with walking and die early. Previous studies on yeast and flies by Dr. Gitler’s team and his collaborators have suggested that mutant ataxin 2 may control the toxicity of TDP-43.
Compared to placebo, injections of the antisense oligonucleotides into the nervous system of the newborn mice extended their median lifespan by 35 percent and improved their ability to walk, while lowering ataxin 2 gene levels in the brain and spinal cord.
The researchers saw similar results when they eliminated ataxin 2 by crossbreeding the TDP-43 mice with mice that are genetically programmed to have no ataxin 2 gene. The offspring lived longer and walked better than the TDP-43 mice. The brains of the offspring also had fewer toxic TDP-43 clusters than the TDP-43 mice.
“Many years of research on yeast and flies laid the ground work for these exciting results,” said Daniel Miller, Ph.D., program director NINDS. “They demonstrate that rigorous studies on simple disease models can lead to powerful insights that help us understand and potentially treat seemingly untreatable disorders.”
Drs. Pulst and Gitler agreed that more research needs to be done before the types of antisense oligonucleotides their teams used can be tested in patients. Both labs are currently taking the next steps by conducting further preclinical experiments.
Learn more: Gene silencing shows promise for treating two fatal neurological disorders
[osd_subscribe categories=’gene-silencing’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “GENE SILENCING”‘]
The Latest on: Gene silencing
[google_news title=”” keyword=”gene silencing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene silencing
- Balancing two forms of SNCA protein could help manage Parkinson’s, study findson May 20, 2024 at 4:00 am
Another workable solution has been to use a gene-silencing tool, like CRISPR-Cas9, at a precise location. Researchers have tried this method in cell cultures and model animals. But a significant ...
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthmaon May 20, 2024 at 3:29 am
NDAQ:ARWR) Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma ...
- Phio Pharmaceuticals Secures New Investoron May 17, 2024 at 8:00 am
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is ...
- Regeneron Gene Therapy Restores Hearing in Infant With Genetic Form of Deafness, Data at ASGCT Showon May 13, 2024 at 12:09 pm
An infant with profound hearing loss caused by a rare genetic condition is now able to hear at near-normal levels after receiving Decibel Therapeutics' experimental gene therapy, and another patient ...
- Researchers clone 'half-tendrilless' gene locus in pea mutant afilaon May 13, 2024 at 8:30 am
Pea is the fourth largest edible legume crop in the world and is widely cultivated throughout the world. Several classical leaf mutants have been identified in peas, including unifoliata (uni), afila ...
- Advancing The Future Of Medicine By Getting Back To Its Genetic Rootson May 9, 2024 at 12:00 pm
Regeneron is rooted in the power of genetics, technology and collaboration—the blueprint for our antibody portfolio and now, genetic medicines. Unlocking innovation to deliver life-altering therapies ...
- Uncovering key players in gene silencing: Insights into plant growth and human diseaseson April 18, 2024 at 5:00 pm
More information: Sridevi Sureshkumar et al, SUMO protease FUG1, histone reader AL3 and chromodomain protein LHP1 are integral to repeat expansion-induced gene silencing in Arabidopsis thaliana ...
- RNAi mediated gene silencingon April 24, 2021 at 6:44 am
Double-stranded RNA can be introduced experimentally to silence genes of interest. In plants, silencing can be triggered, for example, by engineering RNA viruses. In worms, silencing can be ...
- DNA methylation and gene silencingon January 27, 2021 at 10:05 am
When methylation affects CpG islands, methyl-binding proteins trigger a silencing cascade (activity ... this complex can be "opened" so that specific genes are expressed.
via Bing News